-transparent.png){kind=logo}
The tryptophan residue of luteinizing-hormone-releasing hormone (luliberin) was chemically modified to produce the following analogs: [Trp(o)3]luliberin, Trp-(2,4-dinitrophenylsulfenyl)-luliberin, Trp-(2-hydroxy-5-nitrobenzyl)luliberin, (Trp-S-luliberin)2, Trp-CH3S-luliberin and Trp-formyl-luliberin. The luteinizing-hormone-releasing activity of those analogs was determined by bioassay in vitro and found to be 0.2%, 0.2%, 0.6%, 1.5%, 1.7% and 7% of that of the natural hormone, respectively. These results demonstrate that alterations in the indole moiety of tryptophan-3, which lead to a reduction in its electron density or sterically restrict its electron avaliability, are associated with a dramatic loss of biological activity.
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
February 1979,
Biochemical Society transactions,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
August 1974,
Biochemistry,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
August 1979,
Journal of medicinal chemistry,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
April 1982,
International journal of andrology,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
September 1981,
The Journal of clinical investigation,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
April 1977,
The New England journal of medicine,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
March 1986,
Archives of internal medicine,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
March 1993,
Acta paediatrica (Oslo, Norway : 1992). Supplement,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
December 1983,
The Biochemical journal,
E Hazum, and
M Fridkin, and
R Meidan, and
Y Koch
June 1975,
The Journal of endocrinology,
